New drug combo tested in fight against tough pancreatic cancer
NCT ID NCT06182072
Summary
This early-stage trial is testing the safety and best dose of a new drug called ProAgio when given alongside standard chemotherapy for advanced pancreatic cancer. It will enroll about 46 adults who have not yet received treatment for their metastatic disease. The main goal is to see if the combination is safe and tolerable, while also gathering initial information on whether it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
O'Neal Comprehensive Cancer Center, University of Alabama
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.